Principal Investigator
Jose Lutzky
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230687
Clinical Trial Summary
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single
Agent and in Combination in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Contact Information
Phone Number
305-243-2647